Bartonellosis
Conditions
Brief summary
Frequency at day 28 of CSD’s adenitis favorable outcome characterized as: Reduction of the volume of the adenitis evaluated by echography of ≥ 80% compared to day 0, Without requirement of supplementary needle aspirations after day 7’s visit, And without requirement of a surgical excision or incision of the adenitis.
Detailed description
Percentage of volume reduction of the adenitis, evaluated by ultrasound between day 0 and day 28, Percentage of reduction of the pain related to the adenitis evaluated by analogic visual scale between day 0, day 7, and day 28, Number of patients with persisting cutaneous fistulization of the adenitis at day 7, and day 28, Number of patients requiring supplementary needle pus evacuation between day 14 and day 28, Number of patients requiring surgical excision or incision of the adenitis, Percentage of decrease of serum Protein C reactive level between day 0 and day 7, Genotypic profile of resistance to macrolides and aminoglycosides, Safety of the intra-nodal injection of gentamicin
Interventions
Sponsors
Eligibility
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency at day 28 of CSD’s adenitis favorable outcome characterized as: Reduction of the volume of the adenitis evaluated by echography of ≥ 80% compared to day 0, Without requirement of supplementary needle aspirations after day 7’s visit, And without requirement of a surgical excision or incision of the adenitis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of volume reduction of the adenitis, evaluated by ultrasound between day 0 and day 28, Percentage of reduction of the pain related to the adenitis evaluated by analogic visual scale between day 0, day 7, and day 28, Number of patients with persisting cutaneous fistulization of the adenitis at day 7, and day 28, Number of patients requiring supplementary needle pus evacuation between day 14 and day 28, Number of patients requiring surgical excision or incision of the adenitis, Percentage of decrease of serum Protein C reactive level between day 0 and day 7, Genotypic profile of resistance to macrolides and aminoglycosides, Safety of the intra-nodal injection of gentamicin | — |
Countries
France